About sanofi - SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.
SNY At a Glance
Sanofi
46, avenue de la Grande Armée
Paris, Ile-de-France 75017
| Phone | 33-1-53-77-40-00 | Revenue | 49.24B | |
| Industry | Pharmaceuticals: Major | Net Income | 8.82B | |
| Sector | Health Technology | 2025 Sales Growth | 10.798% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
SNY Valuation
| P/E Current | 13.146 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.414 |
| Price to Sales Ratio | 2.402 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 9.75 |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | 2.713 |
| Total Debt to Enterprise Value | 0.179 |
SNY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 105.597 |
| Total Asset Turnover | 0.344 |
SNY Liquidity
| Current Ratio | 1.092 |
| Quick Ratio | N/A |
| Cash Ratio | 0.27 |
SNY Profitability
| Gross Margin | 70.089 |
| Operating Margin | 32.666 |
| Pretax Margin | 14.154 |
| Net Margin | 17.909 |
| Return on Assets | 3.892 |
| Return on Equity | 6.794 |
| Return on Total Capital | 5.175 |
| Return on Invested Capital | 5.675 |
SNY Capital Structure
| Total Debt to Total Equity | 28.482 |
| Total Debt to Total Capital | 22.168 |
| Total Debt to Total Assets | 16.032 |
| Long-Term Debt to Equity | 22.017 |
| Long-Term Debt to Total Capital | 17.136 |
Sanofi in the News
Sanofi takes another big hit as it halts work on breast cancer medication, amcenestrant
French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial.
Possible new Sanofi-GSK coronavirus vaccine showing promise in trials, companies say
A possible new coronavirus vaccine candidate produced by Sanofi and GSK (GlaxoSmithKline) that uses the human body’s own antigens to neutralize antibody responses for people who have already recovered from the illness, has completed Phase 2 trials, the companies said Monday.
Next generation coronavirus vaccine in pill, spray forms could have these benefits, Dr. Nesheiwat explains
Fox News medical contributor Dr. Janette Nesheiwat broke down to "Kudlow" that a wider range of coronavirus vaccine options would be beneficial for pandemic recovery as well as personal health.